Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
Jonas Sundén-CullbergPuran ChenHenrike HäbelPaul SkorupHelena JanolsJohan RasmusonKatarina NiwardÅse Östholm BalkhedKaterina ChatzidionysiouHilmir AsgeirssonOla BlennowÅsa ParkeAnna-Karin SvenssonJagadeeswara Rao MuvvaHans-Gustav Ljunggrennull nullAnna-Carin HorneUlrika ÅdénJan-Inge HenterAnders SönnerborgJan VesterbackaPiotr NowakJon LampaPublished in: PloS one (2023)
Premature closure of trial precludes firm conclusions. Anakinra or tocilizumab did not significantly shorten time to clinical recovery compared to usual care. (IMMCoVA, NCT04412291, EudraCT: 2020-00174824).
Keyphrases
- phase iii
- open label
- phase ii
- study protocol
- rheumatoid arthritis
- clinical trial
- healthcare
- coronavirus disease
- juvenile idiopathic arthritis
- sars cov
- rheumatoid arthritis patients
- palliative care
- phase ii study
- early onset
- disease activity
- squamous cell carcinoma
- emergency department
- placebo controlled
- double blind
- radiation therapy
- pain management
- adverse drug
- drug induced
- health insurance